Related references
Note: Only part of the references are listed.Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC)
Yong Chen et al.
BIOORGANIC CHEMISTRY (2022)
Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways
Miao Yu et al.
ACTA PHARMACOLOGICA SINICA (2021)
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
E. Dianne Pulte et al.
CLINICAL CANCER RESEARCH (2021)
Advances in acute myeloid leukemia
Laura F. Newell et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Advancing targeted protein degradation for cancer therapy
Brandon Dale et al.
NATURE REVIEWS CANCER (2021)
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Hitoshi Kiyoi et al.
CANCER SCIENCE (2020)
Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD
Cong Liang et al.
LEUKEMIA & LYMPHOMA (2020)
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
Katherine A. Donovan et al.
CELL (2020)
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
Sebastian Scholl et al.
CELLS (2020)
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
Vanessa E. Kennedy et al.
FRONTIERS IN ONCOLOGY (2020)
RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia
S. Rudat et al.
LEUKEMIA (2018)
ETV6/FLT3 Fusion Is a Novel Client Protein of Hsp90
Bui Thi Kim Ly et al.
ONCOLOGY RESEARCH (2018)
Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
Kozo Nagai et al.
Oncotarget (2018)
Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
George M. Burslem et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Hai-Tsang Huang et al.
CELL CHEMICAL BIOLOGY (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways
Li-Na Wang et al.
LEUKEMIA & LYMPHOMA (2017)
Inhibition of USP10 induces degradation of oncogenic FLT3
Ellen L. Weisberg et al.
NATURE CHEMICAL BIOLOGY (2017)
Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells
Clement Larrue et al.
BLOOD (2016)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 Gatekeeper F691L Mutation with PLX3397
Catherine C. Smith et al.
CANCER DISCOVERY (2015)
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors
Marije Slingerland et al.
ANTI-CANCER DRUGS (2014)
Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies
Christine M. Lovly et al.
CLINICAL CANCER RESEARCH (2014)
Targeting Oncoprotein Stability Overcomes Drug Resistance Caused by FLT3 Kinase Domain Mutations
Chuanjiang Yu et al.
PLOS ONE (2014)
Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells
Bui Thi Kim Ly et al.
PLOS ONE (2013)
c-Cbl and Cbl-b Ligases Mediate 17-Allylaminodemethoxygeldanamycin-induced Degradation of Autophosphorylated Flt3 Kinase with Internal Tandem Duplication through the Ubiquitin Proteasome Pathway
Gaku Oshikawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Ubiquitin becomes ubiquitous in cancer Emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets
Dingding Shi et al.
CANCER BIOLOGY & THERAPY (2010)
Prevalence and Prognostic Significance of FLT3 Gene Mutations in Patients with Acute Leukaemia: Analysis of Patients from the Shanghai Leukaemia Co-operative Group
W. Wang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2010)
Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation
M. Buchwald et al.
LEUKEMIA (2010)
Drug resistance in mutant FLT3-positive AML
E. Weisberg et al.
ONCOGENE (2010)
Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling
Laila Al Shaer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Stefan Froehling et al.
CANCER CELL (2007)
Flt3-dependent transformation by inactivating c-Cbl mutations in AML
Buelent Sargin et al.
BLOOD (2007)
Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51
Qing Yao et al.
CLINICAL CANCER RESEARCH (2007)
Drug discovery in the ubiquitin-proteasome system
Grzegorz Nalepa et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway
Q Yao et al.
LEUKEMIA (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3
P Bali et al.
CLINICAL CANCER RESEARCH (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors
Y Minami et al.
LEUKEMIA (2002)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Share Paper
